We are live on
!
Find out more
TAM
Tiverton Asset Management Portfolio holdings
AUM
$2.88B
1-Year Est. Return
5.6%
This Fund
S&P 500
This Quarter
Est. Return
+16.23%
1 Year Est. Return
+5.6%
3 Year Est. Return
+61.83%
5 Year Est. Return
+105.31%
10 Year Est. Return
–
AUM
$2.31B
AUM Growth
+$641M
(+38%)
Cap. Flow
+$372M
Cap. Flow
% of AUM
16.15%
Top 10 Holdings %
Top 10 Hldgs %
31.4%
Holding
680
New
190
Increased
323
Reduced
69
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$9.6M |
| 2 |
A.O. Smith
AOS
|
+$7.79M |
| 3 |
JPMorgan Chase
JPM
|
+$7.71M |
| 4 |
Microsoft
MSFT
|
+$6.58M |
| 5 |
Bank of America
BAC
|
+$6.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$7.15M |
| 2 |
Pediatrix Medical
MD
|
+$3.07M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$2.05M |
| 4 |
Wayfair
W
|
+$1.83M |
| 5 |
Arrowhead Research
ARWR
|
+$1.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.94% |
| 2 | Healthcare | 15.67% |
| 3 | Financials | 12.57% |
| 4 | Consumer Discretionary | 11.83% |
| 5 | Miscellaneous | 11.53% |
Similar funds
TAM
RCM
NA
FCM
STMM
CC
CA
BA
Tiverton Asset Management's Q1 2019 Portfolio in Review
As of Q1 2019, Tiverton Asset Management held 680 positions worth $2.31B, up 38% from $1.66B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Tiverton Asset Management deployed $372M of net new capital in Q1 2019, opening 190 new positions and adding to 323 existing holdings. Its largest new stake was Pfizer: 104,318 shares worth $4.2M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Celgene Corp, an estimated $7.15M trimmed.
- Tiverton Asset Management's largest Q1 2019 buy was Pfizer: 104,318 shares worth $4.2M.
- Tiverton Asset Management added most to Alphabet (Google) Class A in Q1 2019, an estimated $9.6M increase.
- Tiverton Asset Management's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $7.15M.
- Tiverton Asset Management fully exited Bristol-Myers Squibb in Q1 2019, selling an estimated $1.07M.
- Tiverton Asset Management's ten largest holdings make up 31% of its $2.31B portfolio in Q1 2019.
- Tiverton Asset Management opened 190 new positions and closed 28 in Q1 2019.
- Tiverton Asset Management's portfolio value rose 38% quarter-over-quarter to $2.31B.
Based on Tiverton Asset Management's 13F filing for Q1 2019, filed 13 May 2019.